Synexus forges ahead with record new business signings, expanded therapeutic offerings and a strengthened board

03 Oct 2011
Synexus, which confidently expects to sign a record amount of new business this year, has expanded its therapeutic offering to its pharma and CROs clients across the world and further strengthened its board. Synexus, based in Manchester, UK, is the largest multinational organisation dedicated to the recruitment of patients and running of clinical trials at its own Dedicated Research Centres across the globe.
Christophe Berthoux, CEO, who has just completed his first year as CEO said: "Synexus has a reputation for leading the industry and for developing innovative and more effective ways of doing things. In order to keep pace with this reputation we have, this year, worked hard to ensure we stay abreast of market changes and have developed a number of new offerings. We have broadened our therapeutic offering into areas such as CNS and ophthalmology and conditions such as asthma and COPD and have combined this with our extended geographical reach and the delivery of quality data on time. This is a very powerful offering which is aligned to the increased outsourcing trend being witnessed in the pharma industry."

Synexus has made significant investment in ensuring its management team and board comprises some of the industry's most innovative and experienced experts who, together, drive the business. In line with this policy Synexus has announced that Alan Pilgrim will join the Board as Chairman. Alan has extensive healthcare experience, having recently retired as Group Chief Executive Officer of Europe's largest diagnostic imaging services company, Alliance Medical. Prior to this he turned around the healthcare staffing business Match Group and was Chief Executive Officer of Community Hospitals Group and Group Managing Director of BNA - now known as Nestor.

Professor Trevor Jones, CBE, who has been chairman of Synexus since 2007, has guided the company through significant changes which saw it more than double its turnover and increase its number of Dedicated Research Centres to 26 across nine countries. Trevor remains on the Board and will become President of the Synexus Scientific Advisory Boards. These advisory boards are focusing on the further development of the Synexus model and are composed of world leading specialists across a variety of therapeutic areas.

Dr Christophe Berthoux continues: "Synexus continues to undergo significant change to meet the ever changing, and demanding, needs of the industry. We have made considerable progress with the expansion of our therapeutic offering and this programme will continue. We are focused on not only meeting but exceeding our client's expectations; our success has been reflected in our growing order book.

I am delighted to welcome Alan as our new Chairman. He will play a major role in the continued changes which will enable Synexus to reposition and continue to grow. I am also particularly pleased that Trevor will continue to play a key role in our business. Our scientific advisory board programme has been very well received by the industry and is integral to ensuring we stay at the forefront of the industry.

Andrew Aylwin, who is one of two Synexus directors from majority shareholder Lyceum Capital commented, "I welcome the changes Synexus is taking. Christophe and his team have some exciting and bold plans for the future. We, at Lyceum, are committed to further supporting these changes and being part of a business which really is shaping the future of the industry. Synexus has huge potential and we look forward to helping them realise that over the next few years."

 

 

Back to top ^

Feasibility

If you would like an assessment on a clinical trial please send us your details and we will get back to you.

Contact Us

Have more questions? Contact us for more information

Contact Us

Synexus Limited, Registered in England and Wales, Registered number 3724238, Registered Office: Sandringham House, Ackhurst Park, Chorley , Lancashire, PR7 1NY